Clarametyx Biosciences Announces $33M Series A Financing to Advance Anti-Biofilm Biologics for Serious Bacterial Infections Newly established relationship with Cystic Fibrosis Foundation enables clinical studies targeting cystic fibrosis-associated infections

# # # #